Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
18.12
-0.24 (-1.31%)
At close: Feb 20, 2026, 4:00 PM EST
20.53
+2.41 (13.30%)
Pre-market: Feb 23, 2026, 7:22 AM EST
Legend Biotech Stock Forecast
Stock Price Forecast
The 13 analysts that cover Legend Biotech stock have a consensus rating of "Buy" and an average price target of $63.46, which forecasts a 250.22% increase in the stock price over the next year. The lowest target is $21 and the highest is $84.
Price Target: $63.46 (+250.22%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $90 → $80 | Buy | Maintains | $90 → $80 | +341.50% | Feb 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $50 | Strong Buy | Maintains | $60 → $50 | +175.94% | Jan 22, 2026 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades $62 → $21 | Strong Buy → Hold | Downgrades | $62 → $21 | +15.89% | Jan 22, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $66 | Buy | Maintains | $66 | +264.24% | Jan 20, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $75 | Buy | Initiates | $75 | +313.91% | Jan 7, 2026 |
Financial Forecast
Revenue This Year
1.05B
from 627.24M
Increased by 67.72%
Revenue Next Year
1.51B
from 1.05B
Increased by 43.82%
EPS This Year
-0.95
from -0.97
EPS Next Year
0.38
from -0.95
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.8B | ||||
| Avg | 1.1B | 1.5B | ||||
| Low | 976.1M | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 82.5% | 74.9% | ||||
| Avg | 67.7% | 43.8% | ||||
| Low | 55.6% | 22.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.41 | 1.04 | ||
| Avg | -0.95 | 0.38 | ||
| Low | -1.61 | -0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.